In Brief: EchoCath/Medtronic
This article was originally published in The Gray Sheet
Executive Summary
EchoCath/Medtronic: Forge strategic alliance for the development of an ultrasound-guided heart pacemaker implantation system. Under an exclusive license agreement, Medtronic gains access to certain EchoCath technologies "to enable the precise positioning with conventional ultrasound imaging systems of pacemaker leads within the heart," EchoCath says. In exchange, Medtronic will make milestone payments to EchoCath and pay royalties on product sales. The system under development "is designed to augment and, in appropriate cases, replace the traditional fluoroscopy to guide placement of leads"...
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.